Cargando…

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) is well recognized for its important role in cholesterol metabolism. Elevated levels are associated with increased cardiovascular risk and inhibition with PCSK9 antibodies (PCSK9i) lowers cardiovascular events in patients with coronar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leucker, Thorsten M., Gerstenblith, Gary, Schär, Michael, Brown, Todd T., Jones, Steven R., Afework, Yohannes, Weiss, Robert G., Hays, Allison G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660736/ https://www.ncbi.nlm.nih.gov/pubmed/32674634 http://dx.doi.org/10.1161/JAHA.120.016263

Ejemplares similares

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
por: Leucker, Thorsten M., et al.
Publicado: (2018)

Effect of Sex on Coronary Endothelial Dysfunction in People Living With HIV
por: Minhas, Anum S., et al.
Publicado: (2022)

Randomized Trial of Anti-inflammatory Medications and Coronary Endothelial Dysfunction in Patients With Stable Coronary Disease
por: Hays, Allison G., et al.
Publicado: (2021)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Coronary endothelial function is directly related to extent of weight loss in obese patients
por: Hays, Allison, et al.
Publicado: (2013)

Coronary endothelial function using 3T MRI is inversely related to body mass index
por: Hays, Allison, et al.
Publicado: (2012)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

Coronary endothelial function is better in healthy premenopausal women than in healthy older postmenopausal women and men
por: Mathews, Lena, et al.
Publicado: (2017)

Local coronary wall eccentricity and endothelial function are closely related in patients with atherosclerotic coronary artery disease
por: Hays, Allison G., et al.
Publicado: (2017)

Regional coronary endothelial dysfunction is related to local epicardial fat in HIV+ patients
por: Hays, Allison, et al.
Publicado: (2016)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

The MRI evaluation of nitric-oxide mediated systemic endothelial function and coronary endothelial function in healthy subjects and patients with coronary artery disease
por: Iantorno, Micaela, et al.
Publicado: (2015)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

Non-Invasive Detection of Coronary Endothelial Response to Sequential Handgrip Exercise in Coronary Artery Disease Patients and Healthy Adults
por: Hays, Allison G., et al.
Publicado: (2013)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021)

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
por: Gibbs, John P., et al.
Publicado: (2016)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Contemporary Management of Dyslipidemia
por: Ferraro, Richard A., et al.
Publicado: (2022)

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
por: Lorenzatti, Alberto J., et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
por: Silla, Alessia, et al.
Publicado: (2023)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015)

PCSK9 Gene Participates in the Development of Primary Dyslipidemias
por: Matías-Pérez, D, et al.
Publicado: (2021)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

Imaging Assessment of Endothelial Function: An Index of Cardiovascular Health
por: Minhas, Anum S., et al.
Publicado: (2022)

Local coronary endothelial dysfunction varies with the extent of coronary disease: a 3 T MRI study
por: Hays, Allison, et al.
Publicado: (2009)

Coronary artery distensibility is impaired in HIV patients without significant coronary atherosclerosis
por: Petrose, Lia, et al.
Publicado: (2016)

Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication
por: Leucker, Thorsten M., et al.
Publicado: (2014)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
por: Metkus, Thomas S., et al.
Publicado: (2022)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Regional coronary endothelial function is related to local coronary wall thickness in CAD patients using 3T MRI
por: Hays, Allison G, et al.
Publicado: (2011)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e263sedkjg4lbve4ni0mjjb1vh